Zura Bio Limited Class A Ordinary Shares (ZURA)
Stock · NASDAQ · Health Care
$3.88as of 10/16/2026
Price chart
Active signals
ZURA Signal Track Record
How signals performed across all stocks →What ZURA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 30 | -0.4% | 47% | September 30, 2026 |
| Bollinger Band Breakout | 19 | -0.6% | 42% | August 24, 2026 |
| Bollinger Band Breakdown | 13 | -11.4% | 23% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +1.2% | 50% | May 21, 2026 |
| Any 20-session window (baseline) | +1.3% | 52% |
Computed by MarketWall from daily closing prices since January 4, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 40
- Website
- zurabio.com/
Fundamentals
- 1-day range
- $4.15$4.5
- Market cap
- $542.44M
- P/E (trailing)
- —
- P/E (forward)
- -6.20
- EPS (trailing)
- $-0.79
- Dividend yield
- —
- Beta
- -0.03
- Avg. volume
- 1.90M
Forecasts
6 analyst ratings
Zura Bio Limited Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Schoch Steven J · June 17, 2026 · Grant51.0K
- Mark Eisner · June 17, 2026 · Grant51.0K
- Becker Daniel J. · June 17, 2026 · Grant51.0K
- Jennifer Jarrett · June 17, 2026 · Grant51.0K
- Amit Munshi · June 17, 2026 · Grant51.0K
- Nirula Ajay · June 17, 2026 · Grant51.0K
- Thiara Parvinder · June 17, 2026 · Grant51.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains
Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains. Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.